EC Number |
Inhibitors |
Structure |
---|
3.6.5.2 | (2E)-2-[(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one |
inhibition of GEF-Rac1 interaction (selective for Trio) |
|
3.6.5.2 | 2-(morpholin-4-ylmethyl)-5-[(5-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]pentyl)oxy]-4H-pyran-4-one |
inhibition of Rac1 nucleotide binding possiblly using an allosteric mechanism |
|
3.6.5.2 | 2-amino-8-hydroxy-9-[3-hydroxy-2-(hydroxymethyl)cyclopentyl]-5,9-dihydro-6H-purin-6-one |
inhibition of Rac1-dependent NADPH oxidase activity |
|
3.6.5.2 | 3-(2-hydroxyphenyl)-N-[4-(piperidin-1-ylsulfonyl)phenyl]-1H-pyrazole-5-carboxamide |
inhibition of GEF-Rac1 interaction (Tiam1, Trio, and Vav2), the compound inhibits lamellipodia formation and smooth muscle cell migration |
|
3.6.5.2 | 3-([(2E)-2-cyano-3-(4-methoxy-3-[(naphthalen-1-ylcarbonyl)oxy]phenyl)prop-2-enoyl]amino)benzoic acid |
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue |
|
3.6.5.2 | 5'-p-fluorosulfonylbenzoylguanosine |
irreversible substrate analogue-binding |
|
3.6.5.2 | 5-(3-chloro-4-[(3-fluorobenzyl)oxy]-5-methoxybenzyl)-1-(4-hydroxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione |
- |
|
3.6.5.2 | 5-chloro-3-(2-oxo-2-(4-[3-(trifluoromethyl)phenyl]piperazin-1-yl)ethyl)-1H-indole-2-carboxylic acid |
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue |
|
3.6.5.2 | 9-methoxy-5-(3-nitrophenyl)-2-phenyl-3,10b-dihydropyrazolo[1,5-c][1,3]benzoxazine |
inhibition of effector-Rac1 interaction (p67phox) |
|
3.6.5.2 | atorvastatin |
marketed as Lipitor, i.e. [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, inhibits RhoA activity by reducing Rho geranylgeranylation |
|